Duration of SHIV production by infected cells is not exponentially distributed: Implications for estimates of infection parameters and antiviral efficacy

Catherine A.A. Beauchemin, Tomoyuki Miura, Shingo Iwami

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The duration of the eclipse phase, from cell infection to the production and release of the first virion progeny, immediately followed by the virus-production phase, from the first to the last virion progeny, are important steps in a viral infection, by setting the pace of infection progression and modulating the response to antiviral therapy. Using a mathematical model (MM) and data for the infection of HSC-F cells with SHIV in vitro, we reconfirm our earlier finding that the eclipse phase duration follows a fat-tailed distribution, lasting 19 h (18-20 h). Most importantly, for the first time, we show that the virus-producing phase duration, which lasts 11 h (9.8-12 h), follows a normal-like distribution, and not an exponential distribution as is typically assumed. We explore the significance of this finding and its impact on analysis of plasma viral load decays in HIV patients under antiviral therapy. We find that incorrect assumptions about the eclipse and virus-producing phase distributions can lead to an overestimation of antiviral efficacy. Additionally, our predictions for the rate of plasma HIV decay under integrase inhibitor therapy offer an opportunity to confirm whether HIV production duration in vivo also follows a normal distribution, as demonstrated here for SHIV infections in vitro.

Original languageEnglish
Article number42765
JournalScientific reports
Volume7
DOIs
Publication statusPublished - Feb 16 2017

Fingerprint

Antiviral Agents
Normal Distribution
HIV
Viruses
Infection
Virion
Integrase Inhibitors
Virus Diseases
Viral Load
Theoretical Models
Therapeutics
Fats
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • General

Cite this

Duration of SHIV production by infected cells is not exponentially distributed : Implications for estimates of infection parameters and antiviral efficacy. / Beauchemin, Catherine A.A.; Miura, Tomoyuki; Iwami, Shingo.

In: Scientific reports, Vol. 7, 42765, 16.02.2017.

Research output: Contribution to journalArticle

@article{dd9bc9a18cce4c3a970f7a0162f9260d,
title = "Duration of SHIV production by infected cells is not exponentially distributed: Implications for estimates of infection parameters and antiviral efficacy",
abstract = "The duration of the eclipse phase, from cell infection to the production and release of the first virion progeny, immediately followed by the virus-production phase, from the first to the last virion progeny, are important steps in a viral infection, by setting the pace of infection progression and modulating the response to antiviral therapy. Using a mathematical model (MM) and data for the infection of HSC-F cells with SHIV in vitro, we reconfirm our earlier finding that the eclipse phase duration follows a fat-tailed distribution, lasting 19 h (18-20 h). Most importantly, for the first time, we show that the virus-producing phase duration, which lasts 11 h (9.8-12 h), follows a normal-like distribution, and not an exponential distribution as is typically assumed. We explore the significance of this finding and its impact on analysis of plasma viral load decays in HIV patients under antiviral therapy. We find that incorrect assumptions about the eclipse and virus-producing phase distributions can lead to an overestimation of antiviral efficacy. Additionally, our predictions for the rate of plasma HIV decay under integrase inhibitor therapy offer an opportunity to confirm whether HIV production duration in vivo also follows a normal distribution, as demonstrated here for SHIV infections in vitro.",
author = "Beauchemin, {Catherine A.A.} and Tomoyuki Miura and Shingo Iwami",
year = "2017",
month = "2",
day = "16",
doi = "10.1038/srep42765",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Duration of SHIV production by infected cells is not exponentially distributed

T2 - Implications for estimates of infection parameters and antiviral efficacy

AU - Beauchemin, Catherine A.A.

AU - Miura, Tomoyuki

AU - Iwami, Shingo

PY - 2017/2/16

Y1 - 2017/2/16

N2 - The duration of the eclipse phase, from cell infection to the production and release of the first virion progeny, immediately followed by the virus-production phase, from the first to the last virion progeny, are important steps in a viral infection, by setting the pace of infection progression and modulating the response to antiviral therapy. Using a mathematical model (MM) and data for the infection of HSC-F cells with SHIV in vitro, we reconfirm our earlier finding that the eclipse phase duration follows a fat-tailed distribution, lasting 19 h (18-20 h). Most importantly, for the first time, we show that the virus-producing phase duration, which lasts 11 h (9.8-12 h), follows a normal-like distribution, and not an exponential distribution as is typically assumed. We explore the significance of this finding and its impact on analysis of plasma viral load decays in HIV patients under antiviral therapy. We find that incorrect assumptions about the eclipse and virus-producing phase distributions can lead to an overestimation of antiviral efficacy. Additionally, our predictions for the rate of plasma HIV decay under integrase inhibitor therapy offer an opportunity to confirm whether HIV production duration in vivo also follows a normal distribution, as demonstrated here for SHIV infections in vitro.

AB - The duration of the eclipse phase, from cell infection to the production and release of the first virion progeny, immediately followed by the virus-production phase, from the first to the last virion progeny, are important steps in a viral infection, by setting the pace of infection progression and modulating the response to antiviral therapy. Using a mathematical model (MM) and data for the infection of HSC-F cells with SHIV in vitro, we reconfirm our earlier finding that the eclipse phase duration follows a fat-tailed distribution, lasting 19 h (18-20 h). Most importantly, for the first time, we show that the virus-producing phase duration, which lasts 11 h (9.8-12 h), follows a normal-like distribution, and not an exponential distribution as is typically assumed. We explore the significance of this finding and its impact on analysis of plasma viral load decays in HIV patients under antiviral therapy. We find that incorrect assumptions about the eclipse and virus-producing phase distributions can lead to an overestimation of antiviral efficacy. Additionally, our predictions for the rate of plasma HIV decay under integrase inhibitor therapy offer an opportunity to confirm whether HIV production duration in vivo also follows a normal distribution, as demonstrated here for SHIV infections in vitro.

UR - http://www.scopus.com/inward/record.url?scp=85012996194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012996194&partnerID=8YFLogxK

U2 - 10.1038/srep42765

DO - 10.1038/srep42765

M3 - Article

C2 - 28202942

AN - SCOPUS:85012996194

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 42765

ER -